Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Anatara Lifesciences Ltd ( (AU:ANR) ) has issued an announcement.
Anatara Lifesciences Ltd has been granted a Hong Kong patent for its GaRP product, a multi-component, multi-coated complementary medicine aimed at addressing chronic gastrointestinal conditions like IBS and IBD. This patent, valid for 20 years, strengthens the company’s intellectual property portfolio and enhances its commercial prospects in the non-prescription gastrointestinal health market, which is valued at US$8 billion in the US alone.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a company focused on developing and commercializing innovative, evidence-based health products to address significant unmet needs, particularly in gastrointestinal tract conditions. The company is committed to delivering real outcomes for patients and creating value for shareholders.
Average Trading Volume: 2,828,541
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$1.28M
For a thorough assessment of ANR stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue